Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus
- 19 April 2022
- journal article
- editorial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 173, 157-158
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes MellitusThe American Journal of Cardiology, 2022
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 DiabetesJAMA, 2022
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialThe Lancet, 2021
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 DiabetesNew England Journal of Medicine, 2021
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trialThe Lancet, 2021
- Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome TrialsThe American Journal of Cardiology, 2021
- Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti‐diabetic therapiesDiabetes, Obesity and Metabolism, 2018
- Obesity and Atrial Fibrillation Prevalence, Pathogenesis, and PrognosisJACC, 2017
- Atrial Natriuretic Peptide in the High Normal Range Is Associated With Lower Prevalence of Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2016
- Meta-Analysis of Cohort and Case–Control Studies of Type 2 Diabetes Mellitus and Risk of Atrial FibrillationThe American Journal of Cardiology, 2011